A5067291402- Multiple Myeloma Research and Treatments
- Lymphoma Diagnosis and Treatment
- Protein Degradation and Inhibitors
- Chronic Lymphocytic Leukemia Research
- Cancer Treatment and Pharmacology
- Amyloidosis: Diagnosis, Treatment, Outcomes
- Peptidase Inhibition and Analysis
- Viral-associated cancers and disorders
- HIV/AIDS drug development and treatment
- Health Systems, Economic Evaluations, Quality of Life
- Clinical practice guidelines implementation
- Economic and Financial Impacts of Cancer
- Chronic Myeloid Leukemia Treatments
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Ubiquitin and proteasome pathways
- CNS Lymphoma Diagnosis and Treatment
- CAR-T cell therapy research
- Cancer therapeutics and mechanisms
- Electronic Health Records Systems
- Pharmaceutical Practices and Patient Outcomes
- Cancer survivorship and care
- Acute Myeloid Leukemia Research
- Neuroendocrine Tumor Research Advances
- Cancer Genomics and Diagnostics
- Lung Cancer Treatments and Mutations
Princess Margaret Cancer Centre
2016-2025
University Health Network
2015-2025
University of Toronto
2015-2024
Cancer Care Ontario
2012-2020
BC Cancer Agency
2018
CancerCare Manitoba
2015-2018
Dalhousie University
2015
McMaster University
2015
Queen Elizabeth II Health Sciences Centre
2015
Juravinski Hospital
2015
Lenalidomide plus dexamethasone is a reference treatment for relapsed multiple myeloma. The combination of the proteasome inhibitor carfilzomib with lenalidomide and has shown efficacy in phase 1 2 study
Purpose For patients with relapsed or refractory aggressive lymphoma, we hypothesized that gemcitabine-based therapy before autologous stem-cell transplantation (ASCT) is as effective and less toxic than standard treatment. Patients Methods We randomly assigned 619 relapsed/refractory lymphoma to treatment gemcitabine, dexamethasone, cisplatin (GDP) cytarabine, (DHAP). B-cell also received rituximab. Responding proceeded collection ASCT. Coprimary end points were response rate after two...
Purpose Lenalidomide is an oral immunomodulatory drug with multiple effects on the immune system and tumor cell microenvironment leading to inhibition of malignant growth. Based encouraging reports lenalidomide in relapsed refractory chronic lymphocytic leukemia (CLL), we investigated first-line use single-agent CLL. Patients Methods Using a starting dose 10 mg/d for 21 days 28-day cycle weekly 5-mg escalations target 25 mg, encountered severe toxicities (tumor lysis, fatal sepsis) first two...
The role of a second autologous stem cell transplant (ASCT) as salvage therapy is unclear, particularly with the availability novel agents to treat progressive multiple myeloma (MM). We retrospectively reviewed all MM patients who received ASCT at our center from March 1992 December 2009. Eighty-one for relapsed MM. median time relapse after first was 39 months (9.83-100). All reinduction before ASCT. high-dose regimen given consisted melphalan (MEL) alone in majority. Complete response,...
The combination of oral weekly cyclophosphamide and alternate day prednisone is a convenient regimen for relapsed/refractory multiple myeloma (MM), we sought to improve its efficacy by adding bortezomib, proteasome inhibitor with proven antimyeloma activity.We conducted phase I-II trial evaluating six dose levels define the maximum tolerated (MTD) this in MM. An additional 10 patients were evaluated at highest level reached.Thirty-seven treated on study. MTD was not defined. Both bortezomib...
Summary Involvement of the central nervous system ( CNS ) in multiple myeloma MM is a rare complication, with reported survival <6 months. This report describes 37 patients leptomeningeal and/or parenchymal brain involvement treated at our institution and identifies factors associated long‐term survival. From J anuary 1999 to D ecember 2010, were evaluated institution. Clinical characteristics, treatment retrospectively collected. disease was present diagnosis 24% relapse 76%. Plasma cell...
Abstract Choosing Wisely® is a medical stewardship and quality improvement initiative led by the American Board of Internal Medicine Foundation in collaboration with leading societies United States. The ASH an active participant project. Using iterative process evidence-based method, has identified 5 tests treatments that some circumstances are not well supported evidence which certain cases involve risk adverse events financial costs low likelihood benefit. recommendations focus on avoiding...
Several cytogenetic abnormalities are associated with poor outcomes in multiple myeloma (MM). We prospectively analyzed the impact of on during phase 2 PX-171-003-A1 study single-agent carfilzomib for relapsed and refractory MM. In response-evaluable population (257/266), fluorescence situ hybridization (FISH)/conventional profiles were available 229 patients; 62 (27.1%) had high-risk cytogenetics—del 17p13, t(4;14) or t(14;16) by interphase FISH deletion 13 hypodiploidy metaphase...
As most chemotherapy is administered in the outpatient setting, patients are required to manage related side effects at home without direct support from health professionals. The Advanced Symptom Management System (ASyMS) has been developed facilitate remote monitoring and management of chemotherapy-related toxicity with cancer, using patient-reported outcomes questionnaires a clinician alerting system.This study aims evaluate usability ASyMS, mobile phone-based technology, perspective...
Renal impairment (RI) is a major complication of multiple myeloma (MM). This study aimed to characterize the single-dose pharmacokinetics (PK) oral proteasome inhibitor, ixazomib, in cancer patients with normal renal function [creatinine clearance (CrCl) ≥90 ml/min; n = 20), severe RI (CrCl <30 14), or end-stage disease requiring haemodialysis (ESRD; 7). PK and adverse events (AEs) were assessed after single 3 mg dose ixazomib. Ixazomib was highly bound plasma proteins (~99%) all groups....
Summary Dexamethasone ± thalidomide with infusion of cisplatin, doxorubicin, cyclophosphamide, and etoposide [D(T) PACE ] is generally reserved as salvage therapy for aggressive multiple myeloma ( MM ) or plasma cell leukaemia PCL resistant to conventional therapies. The efficacy durability this potentially toxic regimen in setting unclear. We identified 75 patients who received D(T) relapsed/refractory at two tertiary care centres: P rincess M argaret H ospital, T oronto ayo C linic A...